FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149529669> ?p ?o ?g. }

• W3149529669 endingPage "202" @default.
• W3149529669 startingPage "190" @default.
• W3149529669 abstract "BackgroundDespite high contagiousness and rapid spread, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to heterogeneous outcomes across affected nations. Within Europe (EU), the United Kingdom (UK) is the most severely affected country, with a death toll in excess of 100,000 as of January 2021. We aimed to compare the national impact of coronavirus disease 2019 (COVID-19) on the risk of death in UK patients with cancer versus those in continental EU.MethodsWe performed a retrospective analysis of the OnCovid study database, a European registry of patients with cancer consecutively diagnosed with COVID-19 in 27 centres from 27th February to 10th September 2020. We analysed case fatality rates and risk of death at 30 days and 6 months stratified by region of origin (UK versus EU). We compared patient characteristics at baseline including oncological and COVID-19–specific therapy across UK and EU cohorts and evaluated the association of these factors with the risk of adverse outcomes in multivariable Cox regression models.FindingsCompared with EU (n = 924), UK patients (n = 468) were characterised by higher case fatality rates (40.38% versus 26.5%, p < 0.0001) and higher risk of death at 30 days (hazard ratio [HR], 1.64 [95% confidence interval {CI}, 1.36–1.99]) and 6 months after COVID-19 diagnosis (47.64% versus 33.33%; p < 0.0001; HR, 1.59 [95% CI, 1.33–1.88]). UK patients were more often men, were of older age and have more comorbidities than EU counterparts (p < 0.01). Receipt of anticancer therapy was lower in UK than in EU patients (p < 0.001). Despite equal proportions of complicated COVID-19, rates of intensive care admission and use of mechanical ventilation, UK patients with cancer were less likely to receive anti–COVID-19 therapies including corticosteroids, antivirals and interleukin-6 antagonists (p < 0.0001). Multivariable analyses adjusted for imbalanced prognostic factors confirmed the UK cohort to be characterised by worse risk of death at 30 days and 6 months, independent of the patient's age, gender, tumour stage and status; number of comorbidities; COVID-19 severity and receipt of anticancer and anti–COVID-19 therapy. Rates of permanent cessation of anticancer therapy after COVID-19 were similar in the UK and EU cohorts.InterpretationUK patients with cancer have been more severely impacted by the unfolding of the COVID-19 pandemic despite societal risk mitigation factors and rapid deferral of anticancer therapy. The increased frailty of UK patients with cancer highlights high-risk groups that should be prioritised for anti–SARS-CoV-2 vaccination. Continued evaluation of long-term outcomes is warranted." @default.
• W3149529669 created "2021-04-13" @default.
• W3149529669 creator A5001248487 @default.
• W3149529669 creator A5001343667 @default.
• W3149529669 creator A5003203912 @default.
• W3149529669 creator A5004474804 @default.
• W3149529669 creator A5004582424 @default.
• W3149529669 creator A5008733981 @default.
• W3149529669 creator A5010612782 @default.
• W3149529669 creator A5013672715 @default.
• W3149529669 creator A5015509025 @default.
• W3149529669 creator A5016458469 @default.
• W3149529669 creator A5017243208 @default.
• W3149529669 creator A5017742868 @default.
• W3149529669 creator A5019807921 @default.
• W3149529669 creator A5020078965 @default.
• W3149529669 creator A5020684039 @default.
• W3149529669 creator A5020991260 @default.
• W3149529669 creator A5022223456 @default.
• W3149529669 creator A5022521906 @default.
• W3149529669 creator A5022702970 @default.
• W3149529669 creator A5022732192 @default.
• W3149529669 creator A5026537362 @default.
• W3149529669 creator A5027094790 @default.
• W3149529669 creator A5029108741 @default.
• W3149529669 creator A5031414207 @default.
• W3149529669 creator A5031666050 @default.
• W3149529669 creator A5034412136 @default.
• W3149529669 creator A5034946806 @default.
• W3149529669 creator A5035175323 @default.
• W3149529669 creator A5035588185 @default.
• W3149529669 creator A5035799376 @default.
• W3149529669 creator A5036133691 @default.
• W3149529669 creator A5036452592 @default.
• W3149529669 creator A5037339388 @default.
• W3149529669 creator A5039375708 @default.
• W3149529669 creator A5040733492 @default.
• W3149529669 creator A5041745367 @default.
• W3149529669 creator A5044256192 @default.
• W3149529669 creator A5044624546 @default.
• W3149529669 creator A5045454738 @default.
• W3149529669 creator A5047644166 @default.
• W3149529669 creator A5048685740 @default.
• W3149529669 creator A5051288319 @default.
• W3149529669 creator A5052090354 @default.
• W3149529669 creator A5053524419 @default.
• W3149529669 creator A5059519339 @default.
• W3149529669 creator A5059910653 @default.
• W3149529669 creator A5060954139 @default.
• W3149529669 creator A5061519814 @default.
• W3149529669 creator A5061758533 @default.
• W3149529669 creator A5063643387 @default.
• W3149529669 creator A5065803904 @default.
• W3149529669 creator A5067643297 @default.
• W3149529669 creator A5069756772 @default.
• W3149529669 creator A5073079268 @default.
• W3149529669 creator A5073308887 @default.
• W3149529669 creator A5073558620 @default.
• W3149529669 creator A5075514238 @default.
• W3149529669 creator A5075891253 @default.
• W3149529669 creator A5079807284 @default.
• W3149529669 creator A5080131386 @default.
• W3149529669 creator A5080265360 @default.
• W3149529669 creator A5082045927 @default.
• W3149529669 creator A5084235244 @default.
• W3149529669 creator A5084814326 @default.
• W3149529669 creator A5085870832 @default.
• W3149529669 creator A5087892889 @default.
• W3149529669 creator A5089070091 @default.
• W3149529669 creator A5089513581 @default.
• W3149529669 creator A5090500701 @default.
• W3149529669 date "2021-06-01" @default.
• W3149529669 modified "2023-10-16" @default.
• W3149529669 title "Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study" @default.
• W3149529669 cites W2019718580 @default.
• W3149529669 cites W2159230388 @default.
• W3149529669 cites W2169151026 @default.
• W3149529669 cites W2517811060 @default.
• W3149529669 cites W2973153606 @default.
• W3149529669 cites W3001195213 @default.
• W3149529669 cites W3002108456 @default.
• W3149529669 cites W3009885589 @default.
• W3149529669 cites W3010839841 @default.
• W3149529669 cites W3011833705 @default.
• W3149529669 cites W3012268121 @default.
• W3149529669 cites W3012690896 @default.
• W3149529669 cites W3012756997 @default.
• W3149529669 cites W3014294089 @default.
• W3149529669 cites W3015599879 @default.
• W3149529669 cites W3015792206 @default.
• W3149529669 cites W3016535995 @default.
• W3149529669 cites W3016746341 @default.
• W3149529669 cites W3023976000 @default.
• W3149529669 cites W3027630905 @default.
• W3149529669 cites W3028965239 @default.
• W3149529669 cites W3030573714 @default.
• W3149529669 cites W3034965161 @default.
• W3149529669 cites W3041356098 @default.

• next